Brief: Heartsciences' Myovista Technology Used To Develop Ai-ECG Algorithm To Identify Patients At Risk Of Adverse Cardiovascular Events
Nov 10 (Reuters) - Heart Test Laboratories Inc HSCS.O :
* HEARTSCIENCES' MYOVISTA® TECHNOLOGY USED TO DEVELOP AI-ECG
ALGORITHM TO IDENTIFY PATIENTS AT HIGH-RISK OF MAJOR ADVERSE
CARDIOVASCULAR EVENTS
Source text for Eikon: ID:nGNEb881Hf
Further company coverage: HSCS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on HeartSciences
See all newsBrief: Heartsciences Files Definitive Proxy Statement For Proposed Business Combination With Fortitude Mining
Brief: Fortitude Provides Second Quarter 2026 Financial And Operating Highlights
Brief: Fortitude Invests $1.0 Million In Heartsciences At A 22% Premium With No Adjustment To The Merger Consideration
Brief: Heartsciences - Files Preliminary Proxy For Business Combination With Fortitude Mining Holdings
Brief: Heartsciences Signs First Saas Revenues Agreement Following Full Launch Of Myovista Insights™